Italy’s Menarini Diagnostics is to distribute the EpiCheck non-invasive bladder cancer urine test from Israel’s Nucleix (see here previously) in Europe. Bladder cancer is the sixth most common cancer as there are approximately 760,000 people in Europe with the disease. … Continue reading →

In tests, the Lung EpiCheck blood test developed by Israel’s Nucleix (reported here previously) detected 85% of early stage lung cancers among smokers and ex-smokers with a high risk for developing the disease. On low-risk individuals, the accuracy increased to … Continue reading →

I reported previously (see here) on Israel’s Nucleix and its innovative blood and urine tests for early-stage cancer diagnostics. Nucleix has just received a grant of 2.5 million Euros from the EU’s Horizon 2020 research and innovation program – its … Continue reading →

I reported previously (Jun 2014) on the non-invasive urine test of Israel’s Nucleix for monitoring bladder cancer treatment. Following a multi-center, 400-patients clinical trial, Nucleix has received the CE Mark allowing it to market Bladder EpiCheck in the E.U. https://www.israel21c.org/bladder-cancer-monitor-gets-ce-mark-lung-cancer-test-next/

Israeli scientists from the Rehovot-based company Nucleix succeeded in developing a first of its kind blood test to diagnose lung cancer long before it spreads in the body, thus increasing the chance of survival. The test examines anomalies of the … Continue reading →

Israeli biotech Nucleix has raised more than $5 million to finance its test for early detection of bladder cancer. Nucleix uses epigenetics (tiny changes in a cell’s DNA) to identify cancer cells. In the future, the product could also be … Continue reading →